Kura Oncology (NASDAQ:KURA) Stock Rating Reaffirmed by JMP Securities

Kura Oncology (NASDAQ:KURA)‘s stock had its “market outperform” rating reiterated by equities research analysts at JMP Securities in a report issued on Monday, Benzinga reports. They presently have a $32.00 price target on the stock. JMP Securities’ price target points to a potential upside of 51.87% from the company’s current price.

KURA has been the subject of several other research reports. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Friday, May 3rd. Finally, Wedbush reissued an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $28.28.

Kura Oncology Price Performance

NASDAQ KURA opened at $21.07 on Monday. The stock has a market capitalization of $1.61 billion, a P/E ratio of -9.71 and a beta of 0.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.67 and a current ratio of 16.67. The business’s fifty day moving average is $20.65 and its two-hundred day moving average is $16.22. Kura Oncology has a 1 year low of $7.41 and a 1 year high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, May 2nd. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.03). Kura Oncology’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.50) earnings per share. On average, research analysts forecast that Kura Oncology will post -2.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Signaturefd LLC increased its holdings in Kura Oncology by 40.4% in the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock worth $72,000 after buying an additional 1,449 shares during the last quarter. Pale Fire Capital SE acquired a new position in shares of Kura Oncology during the 3rd quarter worth $92,000. E Fund Management Co. Ltd. lifted its stake in shares of Kura Oncology by 12.2% in the 3rd quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock valued at $109,000 after purchasing an additional 1,301 shares during the last quarter. SG Americas Securities LLC acquired a new position in Kura Oncology during the first quarter worth $110,000. Finally, AXQ Capital LP acquired a new position in shares of Kura Oncology during the 3rd quarter valued at about $118,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.